With alternative technologies available, we should be seeking antibody alternatives that avoid the unnecessary use of animals in research, urges Dr Davi.
Aptamer Group PLC on Thursday announced a cost-cutting drive as it aims to break even within two years.
The York-based biotech firm that makes synthetic antibodies capable of binding to targets such.
Oligonucleotide affinity ligands developer Aptamer Group has developed a panel of binders to a novel Alzheimer’s disease biomarker, patented by partners at Neuro-Bio, following the demonstration of performance in specifically binding to the target biomarker and functionality in a nasal mucous matrix. Click to read more.